This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly. The purpose of this study is to investigate any side effects that may happen with CTX001, how CTX001 is absorbed by and processed in the body, and how CTX001 affects iron levels in the blood when administered with or without iron and/or food.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timeframe: From first dose of study drug through the last study visit, approximately 15 days.
Number of Participants with Serious TEAEs
Timeframe: From first dose of study drug through the last study visit, approximately 15 days.
Number of Participants with Clinically Significant Changes in Physical Examination
Timeframe: From the first dose of study drug through the last study visit; approximately 15 days.
Number of Participants with Clinically Significant Changes in Safety Laboratory Values
Timeframe: From first dose of study drug through last study visit, approximately 15 days.
Number of Participants with Clinically Significant Changes in Vital Signs
Timeframe: From the first dose of study drug through the last study visit, approximately 15 days.
Number of Participants with Clinically Significant Changes in Electrocardiograms
Timeframe: From the first dose of study drug through the last study visit, approximately 15 days.